Jan 15, 2026 04:06PM PainReform changes name to PRF Technologies after diversification

Jan 12, 2026 09:03AM PainReform's OcuRing-K platform shows favorable safety in early studies

Dec 2, 2025 09:15AM PainReform begins development plan for OcuRing-K phase II trial

Oct 1, 2025 09:29AM PainReform reduces losses, completes LayerBio investment

Aug 19, 2025 08:32AM PainReform's DeepSolar unit joins NVIDIA Connect Program

Jul 10, 2025 08:32AM PainReform invests $3 million in LayerBio for eye surgery pain tech

Apr 7, 2025 05:00PM PainReform (PRFX) Provides Year-End Business Update

Mar 5, 2025 11:00AM PainReform (PRFX) Completes Strategic Acquisition of DeepSolar

Feb 18, 2025 08:31AM PainReform (PRFX) Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity

Dec 27, 2024 08:30AM PainReform (PRFX) Provides Further Update on Phase 3 Clinical Trial of PRF-110

Nov 7, 2024 05:00PM PainReform (PRFX) Receives Nasdaq Non-compliance Notice

Oct 24, 2024 09:19AM Maxim Group Downgrades PainReform Ltd. (PRFX) to Hold

Sep 10, 2024 09:47AM PainReform (PRFX) Announces Exercise of Warrants for $1.58 Million Gross Proceeds

Aug 21, 2024 08:36AM PainReform (PRFX) Bunionectomy Study Observations Confirm Optimal Delivery Method for PRF-110 in Bunionectomy Procedures

Aug 20, 2024 08:31AM PainReform (PRFX) Announces Positive Safety Profile for PRF-110

Aug 12, 2024 09:02AM PainReform (PRFX) Announces Development and Successful Manufacturing of New Formulations Providing Anti-Inflammatory and Extended Analgesic Effects

Aug 7, 2024 10:01AM PainReform (PRFX) Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses

Jul 24, 2024 08:31AM PainReform (PRFX) Files Patent Covering Highly Scalable Manufacturing Process for PRF-110 Following Successful Completion and Testing